Nebicapone

Nebicapone

Chemical structure of Nebicapone

Nebicapone is a pharmaceutical compound that acts as a catechol-O-methyltransferase (COMT) inhibitor. It is primarily used in the treatment of Parkinson's disease to enhance the effects of levodopa, a common medication used to manage the symptoms of this neurodegenerative disorder.

Mechanism of Action

Nebicapone works by inhibiting the enzyme catechol-O-methyltransferase (COMT). This enzyme is responsible for the breakdown of catecholamines, including dopamine, in the brain. By inhibiting COMT, nebicapone increases the availability of dopamine, thereby enhancing the therapeutic effects of levodopa in patients with Parkinson's disease.

Pharmacokinetics

Nebicapone is administered orally and is absorbed into the bloodstream where it exerts its effects. The pharmacokinetic profile of nebicapone includes its absorption, distribution, metabolism, and excretion, which are important for determining the appropriate dosing regimen for patients.

Clinical Use

Nebicapone is used as an adjunct therapy in the management of Parkinson's disease. It is particularly beneficial in patients who experience "wearing-off" symptoms, where the effects of levodopa diminish before the next dose is due. By prolonging the action of levodopa, nebicapone helps to reduce motor fluctuations and improve overall symptom control.

Side Effects

Common side effects of nebicapone include nausea, dizziness, and dyskinesia. As with other COMT inhibitors, there is a risk of liver toxicity, and liver function tests are recommended during treatment.

Related Pages

• Parkinson's disease
• Levodopa
• Catechol-O-methyltransferase
• Dopamine